Therapeutic Asset Ratings

361 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Phentermine Obesity	Russell McCulloh, MD	P4	BBB (73)
Cagrilintide Obesity	Novo Nordisk A/S	P3	BBB (72)
Survodutide Obesity	Boehringer Ingelheim	P3	BBB (72)
Mazdutide Obesity	China National Center for Cardiovascular Diseases	P4	BB (70)
Semaglutide Obesity	Ali Aminian	P4	BB (70)
Sibutramine Obesity	Falquetomed	P4	BB (70)
Tirzepatide Obesity	Royal North Shore Hospital	P4	BB (70)
Exenatide Obesity	Vivani Medical, Inc	P4	BB (69)
Liraglutide Obesity	Ali Aminian	P4	BB (69)
Bxcl501 Obesity	Tanta University	P4	BB (68)
Metformin Obesity	Ali Aminian	P4	BB (68)
Orlistat Obesity	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	P4	BB (68)
TESTOSTERONE UNDECYLATE Obesity	Royal College of Surgeons, Ireland	P4	BB (68)
Topamax Obesity	Ali Aminian	P4	BB (68)
Wellbutrin Obesity	Yale University	P4	BB (68)
Orforglipron Obesity	Eli Lilly and Company	P3	BB (68)
Dapagliflozin Obesity	Sultan Qaboos University	P4	BB (67)
Glucagon Obesity	Columbia University	P4	BB (67)
Letrozole Obesity	Sultan Qaboos University	P4	BB (67)
Naltrexone Obesity	Yale University	P4	BB (67)
Acetylsalicylic Acid Obesity	Fundació d'investigació Sanitària de les Illes Balears	P4	BB (66)
AMLODIPINE Obesity	Vanderbilt University Medical Center	P4	BB (66)
apd356 Obesity	Kanion & Huawe Medicine Co.,Ltd	P4	BB (66)
Oxytocin Obesity	University Hospital, Gentofte, Copenhagen	P4	BB (66)
PROPOFOL Obesity	Ataturk University	P4	BB (66)

Showing 1 to 25 of 361 assets

PreviousPage 1 of 15Next